Molecularly targeted immunotherapy used to treat a novel overlap syndrome of pediatric N‐methyl‐ d‐aspartate receptor encephalitis (NMDARE) and possible neurosarcoidosis

Abstract

Abstract Objective Overlap syndromes have been described between N‐methyl‐ d‐aspartate receptor encephalitis (NMDARE) and other neuroinflammatory conditions, although rarely involving neurosarcoidosis. Molecularly targeted immunotherapy may be helpful in the empiric treatment of these conditions. Methods We describe a 9‐year‐old boy with new‐onset seizures and worsening encephalopathy. Results Initial evaluation was concerning for neurosarcoidosis, including elevated cerebrospinal fluid (CSF) and serum angiotensin‐converting enzyme and leptomeningeal with multiple cranial nerve enhancement on magnetic resonance imaging. CSF and serum cytokine profiles were used to choose targeted empiric immunotherapy, and the boy's seizure burden and encephalopathy improved after treatment with tocilizumab. The NMDA receptor antibody titer was later found to be elevated, raising suspicion for a novel overlap syndrome. Interpretation Our patient met the criteria for definite NMDARE and possible neurosarcoidosis. Given the mixed radiographic and serologic markers in this child, cytokine levels were used to direct the choice of empiric treatment, resulting in excellent clinical response. This case suggests that targeted immunotherapy informed by cytokine testing may be helpful in cases of high‐acuity pediatric neuroinflammatory disease with limited diagnostic clarity.

Keywords

• neuroimmunology
• neurosarcoidosis
• N‐methyl‐ d‐aspartate receptor encephalitis
• targeted immunotherapy
• tocilizumab